SVRA
Savara, Inc.
$5.92
+$0.02 (+0.34%)Today
Key Statistics
Market cap1.21B
Price-Earnings ratio-20.14
Dividend yield—
Average volume2.45M
High today$6.00
Low today$5.84
Open price$5.90
Volume590.9K
52 Week high$7.00
52 Week low$1.98
Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.